Map opportunity against adjacent art
Combine patent analytics, scientific publications, product releases and internal experiments to identify under-explored application areas.
Corporate R&D teams need evidence linking technical experiments to market opportunities and intellectual-property choices. An effective program separates the value of a discovery from the number of patents filed or prototypes completed.

Corporate R&D teams need evidence linking technical experiments to market opportunities and intellectual-property choices. An effective program separates the value of a discovery from the number of patents filed or prototypes completed.
For corporate r&d directors and patent portfolio teams, the relevant challenge is to translate research programs into technology roadmaps, portfolio strategy and commercialization decisions. A useful assignment should separate the client’s preferred outcome from what the available evidence can genuinely demonstrate. That means fixing the scope before collecting documents, and identifying which comparisons would have practical consequences for investment, contracting, research or implementation.
The project should clarify who can authorize each action, how long an assumption remains valid and which external evidence or independent specialist is needed. Source-based research helps a decision maker compare credible options while leaving formal legal, technical certification, clinical or financial determinations to their proper authorities.
Combine patent analytics, scientific publications, product releases and internal experiments to identify under-explored application areas.
Rank experiments by hypotheses, testability, reproducibility, cost and possible partner interest. Preserve failed trials as useful decision evidence.
Compare internal use, licensing, collaboration and spinout options with access to manufacturing, channels and complementary IP.
A source register should record document ownership, date, geographic scope, available reproduction detail, conflicts and access limitations. This prevents a comparison of unlike documents from being presented as a verified conclusion.
This evidence stream should be supplied or independently located, dated and tagged to a responsible owner. For corporate r&d directors and patent portfolio teams, the reviewer should record version differences, missing permissions, dependencies and material contrary evidence before relying on it for the proposed decision.
This evidence stream should be supplied or independently located, dated and tagged to a responsible owner. For corporate r&d directors and patent portfolio teams, the reviewer should record version differences, missing permissions, dependencies and material contrary evidence before relying on it for the proposed decision.
This evidence stream should be supplied or independently located, dated and tagged to a responsible owner. For corporate r&d directors and patent portfolio teams, the reviewer should record version differences, missing permissions, dependencies and material contrary evidence before relying on it for the proposed decision.
These are illustrative outputs for a possible engagement and are not assertions about previous client projects, regulated representation or guaranteed performance.
A structured R&D patent intelligence brief would identify source material, decision assumptions, options considered and unresolved questions. It should state what was actually examined, which conclusions depend on management inputs and what requires an external specialist. The format can be adapted to the decision, evidence maturity and geographic scope.
A structured whitespace and adjacent technology map would identify source material, decision assumptions, options considered and unresolved questions. It should state what was actually examined, which conclusions depend on management inputs and what requires an external specialist. The format can be adapted to the decision, evidence maturity and geographic scope.
A structured transfer/licensing experiment plan would identify source material, decision assumptions, options considered and unresolved questions. It should state what was actually examined, which conclusions depend on management inputs and what requires an external specialist. The format can be adapted to the decision, evidence maturity and geographic scope.
A materials R&D team is considering industrial licensing for a laboratory method. The study maps patent clusters, missing scale-up evidence and potential licensee requirements before a costly pilot.
The scenario illustrates how a research assignment might be scoped. It does not describe a named client, actual transaction, verified operating result or completed engagement. An initial assessment should include at least one adverse hypothesis and specify what evidence would lead the decision maker to postpone, narrow or abandon the proposed step.
The right measures are those that connect the proposed work to a decision. Each should identify an observation period, a method, an accountable owner and reasons why the indicator might be misleading:
Use a baseline comparison where possible. Preserve missing information as missing rather than converting it into a positive score. If different evidence sources cannot be normalized fairly, report them in parallel with an explicit explanation of the trade-off.
Agree the exact corporate r&d department decision and its accountable owner; describe available resources, countries, time horizon and which outcomes would justify changing course.
Record sources, dates, ownership, permissions, uncertainty and negative evidence. A slide, product claim or patent family alone is not sufficient to establish operational or commercial suitability.
Compare a conservative baseline, an achievable pilot and a more ambitious alternative for corporate r&d directors and patent portfolio teams. Write down assumptions, costs, failure conditions and the evidence needed to discriminate between them.
Provide a concise source-linked research note with confidence grades, identified handoffs, action owners and next tests. Update the register as material facts change.
Landscape analysis is not a patent validity opinion, guaranteed exclusivity or certified freedom-to-operate assessment.
Scope, staffing and use of third-party materials must be agreed for the actual engagement. Advice that involves a regulated activity, professional opinion or independently certified outcome requires separate assessment by appropriately qualified professionals. Nothing on this page asserts that a particular credential, authorization or prior client result has been established.
Primary institutional reference: https://www.wipo.int/en/web/patent-analytics
The institutional reference provides background context, not a certification of this consulting practice. Its applicability to a particular project must be checked against the source date, context and jurisdiction.
Begin with the decision owner, a one-page statement of the decision, its deadline, a description of the available records and an explicit list of questions that would change the result. This avoids commissioning research that cannot affect an actual investment or operating choice.
No. The work products described here are research and commercial decision-support formats. Patent filing, regulatory approval, securities advice, audit certification, jurisdiction-specific legal opinions and other reserved activities require qualified professionals and separate authorization.
Share a short, non-confidential summary of the technical or commercial problem, the countries involved, the decision date and the form of output needed. Sensitive source material should be exchanged only after an appropriate confidential intake process is agreed.
Send a non-confidential outline of the problem, decision owner, intended deliverable and timing. We can clarify a research-first scope and identify where specialist professional involvement is necessary.